Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Yian Zhang, Bingzong Li, Junling Zhuang, Pengcheng He, Xingli Zhao, Baijun Fang, Songfu Jiang, Bing Chen, Zhongjun Xia, Zhenyu Li, Zengjun Li, Haifeng Zhao, Dawei Ding, Qianqian Zhang, Xunqiang Wang, Peng Liu

Blood (2025) 146 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2025-2279

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage

Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Fang Zheng, Jie Liu, Ling Li, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3451.

https://doi.org/10.1182/blood-2025-3451

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Yunya Luo, Mei Lan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Heng Li, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2025-3450

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Yunya Luo, Mei Lan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2025-1675

Published: 2025

Journal Articles

Safety, tolerability and efficacy of mesutoclax to treat patients with myeloid malignancies

Qian Jiang, Huafeng Wang, Xingli Zhao, Suning Chen, Shuo Ma, Di Zhu, Weige Wang, Renbin Zhao, Jie Jin

Blood (2025) 146 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2025-3417

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

Fang Zheng, Xiaohui SUO, Jie Liu, Liyun Zhao, Guanchen Bai, Xingli Zhao, Yanliang Bai, Dongmei Wang, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2025-3395

Published: 2025

Journal Articles

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

Jian Huang, Tian Zeng, Xiudi Yang, Xingli Zhao, Guangxun Gao, Hu Zhou, Hongyan Tong

Blood (2025) 146 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2025-2034

Published: 2025

Journal Articles

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

Congcong Zhang, Xiaohui SUO, Xingli Zhao, Guanchen Bai, Yanliang Bai, Hongling Peng, Fang Zheng, Dongmei Wang, Liyun Zhao, ZePing Zhou, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2025-1618

Published: 2025

Journal Articles

7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia

Xiaohan Zhang, Xiaohui SUO, Guanchen Bai, Xingli Zhao, Yanliang Bai, Hongling Peng, Fang Zheng, Dongmei Wang, Liyun Zhao, ZePing Zhou, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1617.

https://doi.org/10.1182/blood-2025-1617

Published: 2025

Journal Articles

Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies

Jianxiang Wang, Guanchen Bai, Pengcheng He, Hao Jiang, Fuling Zhou, Wei Yang, Xingli Zhao, Shuning Wei, Zhen Wang, Wenwei Zhu, Lin Geng, Zhihua Zhang, Jianhua Qu, Jie Zhou, Tiejun Gong, Ligen Liu, Junfeng Zhu

Blood (2025) 146 (Supplement 1): 5196.

https://doi.org/10.1182/blood-2025-5196

Published: 2025

Journal Articles

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Yan Huang, Yanyan Liu, Hongming He, Zhiming Li, Ningjing Lin, Ou Bai, Caixia Li, Xiaobo Wang, Yajun Li, Xingli Zhao, Huijing Wu, Xiaorui Fu, Zhihua Yao, Jiuyang Zhang, Ying Chen, Wei Meng, Zhuli Wu, Wenzhi Tian, Yuqin Song

Blood (2025) 146 (Supplement 1): 5358.

https://doi.org/10.1182/blood-2025-5358

Published: 2025

Journal Articles

Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-Risk AML

Shulian Chen, Xiaoyu Zhang, Yi He, Sizhou Feng, Mingzhe Han, Xingli Zhao, Jie Bai, Lijuan Li, Zhihua Zhang, Wang Ying, Jianxiang Wang, Weihua Zhai, Erlie Jiang

Blood (2024) 144 (Supplement 1): 6054.

https://doi.org/10.1182/blood-2024-202404

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Lei Ju, Xingli Zhao, Xiaohui Suo, ZePing Zhou, Yanliang Bai, Yunya Luo, Sifeng Gao, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Yaxian Tan, Guanchen Bai, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 1505.

https://doi.org/10.1182/blood-2024-202971

Published: 2024

Journal Articles

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Wenbing Duan, Chunkang Chang, Zhiguo Wang, Hongbing Ma, Min Ouyang, Xingli Zhao, Lifan Tu, Guodong Wu, Xunqiang Wang, Xiao Jun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 1504.

https://doi.org/10.1182/blood-2024-204972

Published: 2024

Journal Articles

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2024-198844

Published: 2024

Journal Articles

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Blood (2024) 144 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2024-203422

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Yanliang Bai, Yunya Luo, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2024-202495

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2024-202430

Published: 2024

Journal Articles

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 4528.

https://doi.org/10.1182/blood-2024-205232

Published: 2024

Journal Articles

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Zepin Zhou, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Zeyan Shi, Yunya Luo, Yaxian Tan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Heng Li, Weihua Zhao, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2023) 142 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2023-179275

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

Safety, tolerability and efficacy of mesutoclax to treat patients with myeloid malignancies

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia

Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-Risk AML

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only